Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Lautenberg Plans Toxic Substances Control Update Bill

This article was originally published in The Tan Sheet

Executive Summary

Introducing a bill to modernize the 36-year-old Toxic Substances Control Act is a priority for Senator Frank Lautenberg in the 113th Congress. Senator David Vitter might introduce his own industry-backed bill to modernize the act.

You may also be interested in...



GRAS Self-Affirmation Fades As Sound Strategy Under FSMA

Experts at a FDLI conference say Food Safety Modernization Act obligations should convince companies to move beyond self-affirming food ingredients as “generally recognized as safe” without notifying FDA. While the GRAS process generally is considered effective, it lacks transparency in some areas.

GRAS Self-Affirmation Fades As Sound Strategy Under FSMA

Experts at a FDLI conference say Food Safety Modernization Act obligations should convince companies to move beyond self-affirming food ingredients as “generally recognized as safe” without notifying FDA. While the GRAS process generally is considered effective, it lacks transparency in some areas.

GRAS Self-Affirmation Fades As Sound Strategy Under FSMA

Experts at a FDLI conference say Food Safety Modernization Act obligations should convince companies to move beyond self-affirming food ingredients as “generally recognized as safe” without notifying FDA. While the GRAS process generally is considered effective, it lacks transparency in some areas.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel